This message was sent to ##Email##
|
|
|
|
| |
Medpage Today
The first lung transplant for a COVID-19 patient in the U.S. made headlines this month, but such cases are likely to be uncommon and have poorer outcomes than typical for lung transplant, one specialist cautioned.
READ MORE
Syfy Wire
What’s the first thing you think of when you hear the word “Segway”? It probably isn't “human organ production.” But thanks to Segway inventor Dean Kamen’s next big idea, that may just be a commonplace connection.
That’s because Kamen and the Advanced Regenerative Manufacturing Institute, a wide-reaching, well-funded consortium he started about four years ago after winning a Department of Defense contract, are looking not just to produce much-needed organs (and ligaments and tendons and such), but to do so on a massive scale, akin to high-tech semiconductor assembly lines.
READ MORE
|
Promoted by
|
|
|
|
 |
The Telegraph
The number of organ transplant operations in the UK has plummeted during lockdown, leaving thousands of patients waiting for surgery, as a fall in violent crime and car accidents has reduced the pool of donors.
Data from NHS Blood and Transplant shows only 265 transplant operations were carried out between April 1 and May 31 of this year, compared with 702 carried out in the same period in 2019.
READ MORE
Hospital Healthcare Europe
This guideline covers people of all ages who need or have had a kidney transplant and those who are donating a kidney.
It also provides advice for transplant and referral centers on how best to run services during the COVID-19 pandemic and to protect staff and patients from infection.
READ MORE
Healio
Patients who underwent heart transplant with or without bridge to transplant left ventricular assist device therapy had superior five-year survival vs. those with LVAD destination therapy when matched on several clinical factors, a study found.
READ MORE
 |
|
Promoted by
Veloxis Pharmaceuticals
Explore some of the many factors that can put a graft at risk, including CYP3A5*1 expression, declining adherence, and nephrotoxicity. In addition, review pharmacokinetic and clinical data that may be relevant to your practice and patients.
See the Video
|
|
Clinical Transplantation
Opioid use after kidney transplant has been shown to be a risk factor for chronic opioid use, which leads to an increased risk of mortality. The purpose of this study was to evaluate the early impact of a multimodal pain regimen and education quality improvement program on opioid use after kidney transplant two months after implementation.
READ MORE
American Journal of Transplantation
Viral‐induced heterologous immunity is considered a barrier to transplantation tolerance. Yet, hepatitis C infected liver transplant patients occasionally achieve operational tolerance. Researchers investigated the mechanisms through which HCV infection modulates donor‐specific T cell responses following LT and the influence of HCV eradication.
READ MORE
Advertisement
Veloxis Pharmaceuticals
Immunosuppressive medications can be a financial burden for kidney transplant patients, potentially costing as much as $10,000 to $14,000 a year. These expenses can have a negative impact on patients’ lives and may play a role in medication nonadherence, which is associated with transplant failure. Learn more about support that is available with a free 30-day trial to allow your patients to start immediately at no cost. And, for patients who are eligible with commercial insurance coverage, a $0 co-pay card offers significant savings.
Find out more
|
American Journal of Transplantation
Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients with COVID‐19. However, outcomes remain poor. Given the likely benefit of cyclosporine due to its antiviral and immunomodulatory effect, researchers have been using it as a strategy in KTRs diagnosed with COVID-19.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
